Pyridine and pyridinone-based factor XIa inhibitors.
Corte, J.R., Fang, T., Hangeland, J.J., Friends, T.J., Rendina, A.R., Luettgen, J.M., Bozarth, J.M., Barbera, F.A., Rossi, K.A., Wei, A., Ramamurthy, V., Morin, P.E., Seiffert, D.A., Wexler, R.R., Quan, M.L.(2015) Bioorg Med Chem Lett 25: 925-930
- PubMed: 25592713 
- DOI: https://doi.org/10.1016/j.bmcl.2014.12.050
- Primary Citation of Related Structures:  
4WXI - PubMed Abstract: 
The structure-activity relationships (SAR) of six-membered ring replacements for the imidazole ring scaffold is described. This work led to the discovery of the potent and selective pyridine (S)-23 and pyridinone (±)-24 factor XIa inhibitors. SAR and X-ray crystal structure data highlight the key differences between imidazole and six-membered ring analogs.
Organizational Affiliation: 
Discovery Chemistry and Cardiovascular Biology, Research and Development, Bristol-Myers Squibb Company, 311 Pennington-Rocky Hill Road, Pennington, NJ 08543, United States. Electronic address: james.corte@bms.com.